Showing results (21-30 of 110) with videos related to
Sort By:
Pageof 11
JCO Oncology Practice|July 10, 2024
Two-to-One Randomization: Rarely AdvisableBoris Freidlin, Edward L KornControlled Clinical Trials|August 6, 2002
A comment on futility monitoringBoris Freidlin, Edward L KornJournal of the National Cancer Institute|September 28, 2017
Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?Boris Freidlin, Edward L KornClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?Edward L Korn, Boris FreidlinBiometrical Journal. Biometrische Zeitschrift|July 12, 2007
A posterior taleEdward L Korn, Boris FreidlinClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2013
Borrowing information across subgroups in phase II trials: is it useful?Boris Freidlin, Edward L KornJournal of the National Cancer Institute|April 5, 2017
Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design ElementsEdward L Korn, Boris FreidlinJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005Edward L Korn, Boris Freidlin, Margaret MooneyClinical Trials (London, England)|April 29, 2010
A general inefficacy interim monitoring rule for randomized clinical trialsBoris Freidlin, Edward L Korn, Robert GrayJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other ApproachesMegan Othus, Boris Freidlin, Edward L KornPageof 11